Advanced Search
ZHANG Xue, LI Dake. Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 894-899. DOI: 10.3971/j.issn.1000-8578.2020.20.0164
Citation: ZHANG Xue, LI Dake. Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 894-899. DOI: 10.3971/j.issn.1000-8578.2020.20.0164
shu

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors

    Graphical Abstract
    • Abstract
  • Immune checkpoint inhibitors(ICIs) has revolutionized the treatment of cancer. However, with the rapid application of CPIs, the immune-related adverse events (irAE) have attracted more and more attention. irAE can occur in almost all organs, but rheumatic irAE seems to have different clinical characteristics. This article reviews the epidemiology, clinical characteristics and management principles of rheumatic irAE caused by ICIs treatment, and discusses its potential pathogenesis.
    • FullText(HTML)
  • loading
    • References (49)
    • Related Articles

Catalog

    Turn off MathJax
    Article Contents

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits： Visits today：

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return